Moderna Just Gave Investors Yet Another Thing to Cheer About

Moderna reported a surprise profitable quarter with $1.31B in revenue (29% YoY growth) and $0.38 EPS, defying analyst expectations of a loss. The company raised full-year guidance and ended with $8.1-8.3B in cash. Its cancer vaccine with Merck showed strong Phase 3 results, reducing melanoma recurrence risk by 42%, while the stock has surged 720% in 2026. However, risks include COVID vaccine sales volatility and significant optimism already priced into the stock.